Ibuprofen 600 Mg Extended Release (er) Single-dose Dental Pain Study
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 196
- 试验地点
- 1
- 主要终点
- Time-weighted Sum of Pain Intensity Difference Score From 0 to 12 Hours (SPID 0-12)
研究概览
简要总结
The purpose of this study is to assess the efficacy and safety of a single dose of an ibuprofen 600 mg extended release formulation in post-operative dental pain. There is concern that the manufacturing process may affect the performance characteristics of the selected prototype. Therefore, two formulations of this prototype manufactured by two different processes, [roller compaction] and [wet granulation] will be included in this study. The preferred prototype manufactured by two different methods will be compared to placebo and each other. This study will also characterize the pharmacokinetic/pharmacodynamic relationship with these formulations.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 16 Years 至 40 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •INCLUSION CRITERIA:
- •Males and females 16 to 40 years of age.
- •Outpatients who undergo surgical extraction of 1-2 third molars, one of which must be a partial or full bony mandibular impaction and have moderate to severe post-operative pain (confirmed by a VAS score of at least 50 mm on a 100 mm VAS) following surgical extraction;
- •Use of only the following preoperative medication(s)/anesthetic(s): short-acting local anesthetic (mepivacaine or lidocaine) with or without vasoconstrictor, nitrous oxide, and/or midazolam;
- •Reliable, cooperative, and of adequate intelligence to record the requested information on the analgesic questionnaire form;
- •Examined by the attending dentist or physician and medically cleared to participate in the study;
- •In general good health and have no contraindications to the study medication.
排除标准
- •EXCLUSION CRITERIA:
- •Pregnancy, as verified by a urine-based pregnancy test, or breast feeding;
- •Presence of a serious medical condition (e.g., poorly controlled hypertension, poorly controlled diabetes, significantly impaired cardiac, renal or hepatic function, poorly-controlled hyper- or hypothyroidism);
- •Use of a prescription or nonprescription drug with which the administration of ibuprofen or any other NSAID is contraindicated;
- •Use of a bisphosphonate (e.g., risedronate [Actonel], alendronate [Fosamax], or ibandronate [Boniva]) in the past 5-years;
- •Acute localized dentalveolar infection at the time of surgery that could confound the post-surgical evaluation;
- •Females who are of child-bearing potential, or post-menopausal for less than 2 years and not using a medically approved method of contraception (i.e., oral, transdermal, or implanted contraceptives, intrauterine device, diaphragm, condom, abstinence, or surgical sterility), or females who test positive on a urine-based pregnancy test;
- •Presence or history (within 2 years of enrollment) of bleeding disorder(s) or peptic ulcer disease;
- •History of alcoholism (i.e., on average, consumes 3 or more alcoholic drinks per day) or substance abuse within the last year, or is currently abusing alcohol or other mood-altering drugs (e.g., cannabis). Patients who are taking CNS or other psychotropic drugs (including St. John's Wort, or any other nutritional supplement known to have psychotropic effects) may be enrolled if they have been on stable doses of medication for at least 2 months, will maintain this dose throughout the study, and their condition is judged by the Principal Investigator to be well-controlled;
- •Habituation to analgesic drugs (i.e., routine use of oral analgesics 5 or more times per week)
- •History of allergic reaction (e.g., asthma, rhinitis, swelling, shock, or hives) to ibuprofen, naproxen, aspirin, or to any other NSAID; or to codeine, hydrocodone, or acetaminophen, or to their combinations;
- •Prior use of any type of analgesic or NSAID five half-lives of that drug or less before taking the first dose of study medication, except for pre-anesthetic medication and anesthesia for the procedure;
- •Ingestion of any caffeine-containing beverages, chocolate, or alcohol 4 hours or less before taking the first dose of study medication;
- •The subject has taken an investigational product or participated in an investigational trial within 30 days of study enrollment;
- •The subject has previously participated in this study;
- •The subject is a member of the study site staff directly involved with the study, an employee of the Sponsor, or a relative of study site personnel directly involved with the study.
研究组 & 干预措施
1
1 x 600 mg ibuprofen IR/ER-roller compaction caplet
干预措施: ibuprofen (Drug)
2
1 x 600 mg ibuprofen IR/ER-Wet granulation caplet
干预措施: ibuprofen (Drug)
3
1x 220 mg naproxen sodium (Aleve caplet)
干预措施: naproxen (Drug)
4
1 x placebo caplet
干预措施: Placebo (Drug)
结局指标
主要结局
Time-weighted Sum of Pain Intensity Difference Score From 0 to 12 Hours (SPID 0-12)
时间窗: Baseline (0 hour) to 12 hours post dose
Pain intensity difference (PID) score based on 4-point categorical pain intensity rating scale. Participants asked, "How much pain do you have at this time?" Range of scale: None (0), Mild (1), Moderate (2), Severe (3). SPID derived by adding the time-weighted sums of PID scores over the time interval. Scores could range from -12 to 36 where higher positive values indicated improvement (decrease in pain intensity).
Time-weighted Sum of Pain Intensity Difference Score From 8 to 12 Hours (SPID 8-12)
时间窗: 8 to 12 hours post dose
PID score based on 4-point categorical pain intensity rating scale. Participants asked, "How much pain do you have at this time?" Range of scale: None (0), Mild (1), Moderate (2), Severe (3). SPID score derived by adding the time-weighted sums of PID scores over the time interval. Scores could range from -4 to 12 where higher positive values indicated improvement (decrease in pain intensity).
次要结局
- Percentage of Participants With Treatment Failure(8, 9, 10, 11, and 12 hours)
- Participant Global Evaluation of Study Medication at 12 Hours(12 hours)
- Time-weighted Sum of Pain Intensity Difference From 0 to 4 Hours (SPID 0-4) and 4 to 8 Hours (SPID 4-8)(0 to 4 hours and 4 to 8 hours)
- Percentage of Participants Achieving First Perceptible Relief Confirmed by Meaningful Relief(15, 30, 45, 60, 90, and 120 minutes and every 60 minutes up to 360 minutes)
- Pain Intensity Difference (PID) Score(15, 30, 45, 60, 90 minutes and 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, and 24 hours)
- Pain Relief Combined With Pain Intensity Difference (PRID) Score(15, 30, 45, 60, 90 minutes and 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, and 24 hours)
- Time-weighted Sum of Pain Relief and Pain Intensity Difference Scores (SPRID)(0 to 4 hours, 4 to 8 hours, 8 to 12 hours, and 0 to 12 hours)
- Time-weighted Sum of Pain Relief Scores (TOTPAR)(0 to 4 hours, 4 to 8 hours, 8 to 12 hours, and 0 to 12 hours)
- Time to First Perceptible Pain Relief(Baseline to 6 hours)
- Time to Treatment Failure(Baseline to 24 hours)
- Time to Meaningful Pain Relief(Baseline to 6 hours)
- Percentage of Participants Achieving Meaningful Pain Relief(15, 30, 45, 60, 90, and 120 minutes and every 60 minutes up to 360 minutes)
- Participant Global Evaluation of Study Medication at 24 Hours(24 hours)
- Pain Relief (PR) Score(15, 30, 45, 60, 90 minutes and 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, and 24 hours)
- Peak Pain Relief Score(Baseline to 12 hours)